CAMBRIDGE, Mass., Dec. 21,
2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced that
James Porter, Ph.D., Chief Executive
Officer, will present at the 42nd Annual J.P. Morgan
Healthcare Conference on Tuesday, January 9,
2024, at 7:30 a.m. PT in San
Francisco.
A live webcast will be available in the Investors section of the
company's website at www.nuvalent.com, and archived for 30 days
following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on creating
precisely targeted therapies for patients with cancer, designed to
overcome the limitations of existing therapies for clinically
proven kinase targets. Leveraging deep expertise in chemistry and
structure-based drug design, we develop innovative small molecules
that have the potential to overcome resistance, minimize adverse
events, address brain metastases, and drive more durable responses.
Nuvalent is advancing a robust pipeline with parallel lead programs
in ROS1-positive and ALK-positive non-small cell lung cancer, a
program in HER2 Exon 20 insertion-positive cancers, and multiple
discovery-stage research programs.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302020634.html
SOURCE Nuvalent, Inc.